ImmunoGen Announces Top-Line Results From Pivotal SORAYA Trial Of Mirvetuximab Soravtansine In Ovarian Cancer; Trial Met Primary Endpoint With Confirmed Objective Response Rate Of 32.4%
by | Nov 30, 2021 | Extra Jobs | 0 comments
Recent Posts
- Spirit Airlines Gets Second Takeover Bid This Year: What Investors Should Know
- Sidus Space Stock Gains After Q4 Results, Clocks 95% Revenue Growth
- Apple App Store Analysis: This Streaming App Passed Disney+ And Netflix Over The Weekend Thanks To Wrestlemania
- $1000 Invested In Best Buy Co 10 Years Ago Would Be Worth This Much
- Here’s How Much $100 Invested In Activision Blizzard 20 Years Ago Would Be Worth Today
Recent Comments